Application of hyperthermia for cancer treatment: Recent patents review

Recent Patents on Anti-Cancer Drug Discovery

Volumn 7, Issue 1, 2012, Pages 64-73

  Soares, Paula I P ^a   Ferreira, Isabel M M ^a   Igreja, Rui A G B N ^a   Novo, Carlos M M ^b   Borges, João P M R ^a  

^a DEPARTAMENTO DE CIÊNCIA DOS MATERIAIS   (Portugal)

^b INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

Cancer treatment; External magnetic field; Hyperthermia; Magnetic nanoparticles

Indexed keywords

MAGNETIC NANOPARTICLE;

CANCER THERAPY; CATHETER ABLATION; DRUG DELIVERY SYSTEM; ELECTROMAGNETIC FIELD; FREQUENCY MODULATOR; HUMAN; HYPERTHERMIC THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATENT; PRIORITY JOURNAL; RADIOFREQUENCY RADIATION; REVIEW;

EID: 83455236471     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489212798358038     Document Type: Review

References (66)

1. GLOBOCAN: Country Fast Stat. Available at: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900#KEY. (Accessed on: April 30, 2011).
2. Robert CB, Donald WK, Raphael EP, Ralph RW, James FH, Emil FIII, et al. Cancer Medicine. 5th ed. Canada 2000.
3. Souhami RL, Tannock I, Hohenberger P, Horiot JC. Oxford Textbook of Oncology. 2nd ed. Oxford. 2002.
4. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004; 56: 1649-59.
5. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005; 26: 3995-4021.
6. Berry C. Progress in functionalization of mNPs for applications in biomedicine. J Phy D: App Phy 2009; 42: 224003.
7. Kita E, Oda T, Kayano T, Sato S, Minagawa M, Yanagihara H, et al. Ferromagnetic nanoparticles for magnetic hyperthermia and thermoablation tharapy. J Phys D: Appl Phys 2010; 43:474011.
8. Wada S, Yue L, Tazawa K, Furuta I, Nagae H, Takemori S, Minamimura T. New local hyperthermia using dextran magnetite complex (DM) for oral cavity: Experimental study in normal hamster tongue. Oral Dis 2001; 7: 192-5.
9. Minev BR. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. 1st ed. Springer: New York 2011.
10. Gordon RT, Hines JR, Gordon D. Intracellular hyperthermia. A biophysical approach to cancer treatment via intracellular temperature and biophysical alterations. Med Hypothesis 1979; 5: 83-102.
11. Jordan A, Wust P, Scholz R, Tesch B, Fähling H, Mitrovics T, et al. Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Int J Hyperthermia 1996; 12: 705-22.
12. Chan DCF, Kirpotin DB, Bunn PA. Synthesis and evaluation of colloidal magnetic iron-oxides for the sitespecific radiofrequencyinduced hyperthermia of cancer. J Magn Magn Mater 1993; 122: 374-8.
13. Matsumine A, Kusuzaki K, Matsubara T, Shintani K, Satonaka H, Wakabayashi T, et al. Novel hyperthermia for metastatic bone tumors with magnetic materials by generating an alternating electromagnetic field. Clin Exp Metastasis 2007; 24: 191-200.
14. Samulski, T.V. Non-invasive apparatus and method for providing RF energy-induced localized hyperthermia. US20056904323 (2005).
15. Kasevich, R.S, Selkowitz, S.M. Microwave devices for medical hyperthermia, thermotherapy and diagnosis. US20016275738 (2001).
16. Turner, P.F., Hagmann, M. Apparatus for creating hyperthermia in tissue. US20097565207 (2009).
17. Hager ED, Dziambor H, Höhmann D, Strama H. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy- resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer 2001; 11(1): 57-63.
18. Sites, J.P., Glassel, P.R., Miller, M.D., Norgaard, C.B., Roman, T.A., Ziebarth, D.J. Perfusion hyperthermia treatment system and method. US20026413233 (2002).
19. Landy, J., Gildersleeve, M., Tseng, Y.W.P. Hyperthermia, system, method and components. US20107819835 (2010).
20. Groth, K.E., Kelly, T.C., Westerbeck, T.L., Blick, G. Treatment of Hepatitis C using hyperthermia. US20026347633 (2002).
21. Groth, K.E., Kelly, T.C., Westerbeck, T.L., Blick, G. Treatment of human herpesviruses using hyperthermia. US20026415797 (2002).
22. Nicholson, J.E. Selective enhancement of hyperthermia in RF and microwave irradiation of diseased or excess tissue. US20006131577 (2000).
23. Kanzius, J. Enhanced systems and methods for re-induced hyperthermia. US20097510555 (2009).
24. Kanzius, J., Steinbrink, W.H., McDonald, R.J., Keating, M.J. Systems and methods for combined RF-induced hyperthermia and radioimmunotherapy. US20097627381 (2009).
25. Guglielmi, G., Ji, C. Endovascular device for hyperthermia and angioplasty and method for using the same. US20006011995 (2000).
26. Kasevich, R.S., Selkowitz, S.M. Microwave systems for medical hyperthermia, thermotherapy and diagnosis. US20006097985 (2000).
27. Kasevich, R.S. Microwave antennas for medical hyperthermia, thermotherapy and diagnosis. US20016233490 (2001) & US20016181970 (2001).
28. Torchia, M.G., Tye, R., Pacak, J.S. Hyperthermia treatment and probe therefor. US20107691100 (2010).
29. Dobson J. MNPs for drug delivery. Drug development research 2006; 67: 55-60.
30. Gray, B.N., Jones, S.K. Targeted hysteresis hyperthermia as a method for treating diseased tissue. US20006167313 (2000) & US20036565887 (2003).
31. Flores, G.P., Batich, C.D. Ferroelectric hyperthermia system and method for cancer therapy. US20067122030 (2006).
32. Flores, G.P., Batich, C.D. Ferroelectric hyperthermia method for cancer treatment. US20097632295 (2009).
33. Jones, S.K., Rutherford, K.F., Ruys, A.J., Gray, B.N. Systems and methods for combined RF-induced hyperthermia and radioimmunotherapy. US20060147381 (2006).
34. Chang, W.H., Kao, C., Lin, C., Wang, S. Thermosensitive nanostructure for hyperthermia treatment. US20070154397 (2007).
35. Raju, B., Savery, D. Ultrasound monitoring and feedback for magnetic hyperthermia. US20090312637 (2009).
36. Marquez, M.A.M., Garcia, E.G., Camacho, M.A.F. Hyperthermia devices and their uses with nanoparticles. US20110034974 (2011).
37. Baldi, G., Bonacchi, D., Innocenti, F., Lorenzi, G., Bitossi, M., Ferruti, P., Ranucci, E., Ricci, A., Franchini, M.G. MNPs for the application in hyperthermia, preparation thereof and use in constructs having pharmacological application. US20100015060 (2010).
38. Haik, Y., Chen, C.J. Magnetic particle composition for therapeutic hyperthermia. US20107842281 (2010).
39. Ueda, T., Abe, M., Handa, H. Applications of alternating fields on magnetic nanoparticles. US20110071335 (2011).
40. Akhtari, M., Engel, J. Use of functionalized magnetic nanoparticles in cancer detection and treatment. US20110044911 (2011).
41. Te, A., Batt, C., Rey, D. Nanoparticle-mediated microwave treatment methods. US20110034916 (2011).
42. Jain TK, Richey J, Strand M, Leslie-Pelecky DL, Flask C, Labhasetwar V. Magnetic nanoparticles with dual functional properties: Drug delivery and magnetic resonance imaging. Biomaterials 2008; 29(29): 4012-21.
43. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Lewis BK, Kalish H, et al. Characterization of biophysical and Metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology 2003; 229(3):838-46.
44. Olsvik O, Popovic T, Skjerve E, Cudjoe KS, Hornes E, Ugelstad J, et al. Magnetic separation techniques in diagnostic microbiology. Clin Microbiol Rev 1994; 7:43-54.
45. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D: Appl Phys 2003; 36: 167-81.
46. Oghabian MA, Farahbakhsh NM. Potential use of nanoparticle based contrast agents in MRI to detect selected molecular targets. J Biomed Nanotech 2010; 6:1-11.
47. Widder KJ, Senyei AE, Scarpelli DG. Magnetic microspheres: a model system for site specific drug delivery in vivo. Proc Soc Exp Biol Med 1978; 58:141-6.
48. Akiyoshi K, Taniguchi I, Fukui H, Sunamoto J. Hydrogel nanoparticle formed by self-assembly of hydrophobized polysaccharide. Stabilization of adriamycin by complexation. Eur J Pharm Biopharm 1996; 42: 286-90.
49. Couvreur P, Kante B, Grislain L, Roland M, Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles. II. Doxorubicin loaded nanoparticles. J Pharm Sci 1982; 71: 790-3.
50. Cuvier C, Roblot-Treupel L, Millot JM, Lizard G, Chevillard S, Manfait M, et al. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol 1992; 44: 509-17.
51. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Cont Rel 2001; 73: 255-67.
52. Sun C, Fang C, Stephen Z, Veiseh O, Hansen S, Lee D, et al. Tumor- targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine (Lond) 2008; 3(4): 495-505.
53. DeNardo SJ, DeNardo GL, Miers LA, Natarajan A, Foreman AR, Gruettner C, et al. Development of tumour targeting bioprobes (111In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res 2005; 11: 7087-92.
54. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med 2001; 7: 1241-4.
55. Poptani H, Puumalainen A, Grohn OHJ, Loimas S, Kainulainen R, Yla-Herttuala S, et al. Monitoring thymidine kinase and gancyclovir induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 1998; 5: 101-9.
56. Francis G, Blankenberg P, Katsikis D, Storrs RW, Beaulieu C, Spielman D, et al. Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood 1997; 89(10): 3778-86.
57. Cerdan S, Lotscher H R, Kunnecke B, Seeling J. Monoclonal antibody- coated magnetite particles as contrast agents in magnetic resonance imaging of tumors Mag. Reson Med 1989; 12: 151-63.
58. Huh YM. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc 2006; 127: 12387-91.
59. Natarajan, A., Denardo, S.J., Denardo, G.L., Gruettnre, C. Sitespecific conjugation of ligands to nanoparticles US20100179303 (2010).
60. McCArthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 2008; 60: 1241-51.
61. Arias JL, Reddy LH, Othman M, Gillet B, Desmaele D, Zouhiri F, Dosio F, Gref R, Couvreur P. Squalene based nanocomposites: a new plataform for the design of multifunctional pharmaceutical theragnostics. ACS Nano 2011; 5(2): 1513-21.
62. Bossmann, S.H., Troyer, D., Basel, M.T., Samarakoon, T.N., Wang, H., Chikan, V., Kroh, F.O., Koper, O.B., Walker, B.R., Leaym, X. MRI and optical assays for proteases. WO2011028698 (2011).
63. West, J.L., Halas, N.J., Hirsch, L.R. Optically-active nanoparticles for use in therapeutic and diagnostic methods. US20036530944 (2003).
64. Gobin, A.M., Zhang, G. Diagnostic and therapeutic nanoparticles. US20110064665 (2011).
65. Persoons, A., Verbiest, T., Gangopadhyay, P. Targeted delivery of biologically active substances using iron oxide/gold core-shell nanoparticles. GB20052415374 (2005).
66. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small 2008; 4(1): 26-49.